MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ
18.43
+0.36
+1.99%
Opening 10:03 11/09 EST
OPEN
18.51
PREV CLOSE
18.07
HIGH
18.53
LOW
17.89
VOLUME
167.81K
TURNOVER
--
52 WEEK HIGH
27.31
52 WEEK LOW
14.00
MARKET CAP
3.45B
P/E (TTM)
-5.0763
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DYN last week (1102-1106)?
Weekly Report · 4h ago
Why Dyne Therapeutics Stock Is In Focus After Wider Quarterly Losses
Simply Wall St · 2d ago
Strong DYNE-251 Data and 2027 Catalysts Support Dyne Therapeutics’ Growth Outlook
TipRanks · 3d ago
Can Dyne Therapeutics (DYN) Justify Its Valuation Following A Wider Loss And FDA Review?
Simply Wall St · 3d ago
Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
Seeking Alpha · 3d ago
Dyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 Milestones
NASDAQ · 3d ago
Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028
NASDAQ · 4d ago
Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate
Benzinga · 4d ago
More
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.

Webull offers Dyne Therapeutics, Inc stock information, including NASDAQ: DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.